Walgreen's stock could be a "risky bet", Barron's contends Walgreen (WAG) is still feeling the sting from when it parted ways with pharmacy-benefit giant Express Scripts (ESRX) on Jan. 1. The two were unable to come to terms on a new contract that would cover more than $5B in business. Walgreen trades at a P/E ratio well below its historical average. But with more pain possibly on the horizon now that Express Scripts has formerly completed its merger with rival Medco Health Solutions, Barron's wouldn't jump in just yet. Reference Link
Express Scripts CEO says Gilead relationship 'important' going forward Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.